Analysis of RAS Mutation and PAX8/PPARγ Rearrangements in Follicular-derived Thyroid Neoplasms in a Korean Population: Frequency and Ultrasound Findings

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2015 May 23

PMID 25999051

Citations 9

Authors

S H Jeong

H S Hong

J J Kwak

E H Lee

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the frequency and ultrasonography (US) findings of RAS mutations and PAX8/PPARγ rearrangements between follicular thyroid adenomas (FTAs) and follicular thyroid carcinomas (FTCs) in a Korean population.

Methods: RAS mutations and PAX8/PPARγ rearrangements in 56 FTAs and 35 FTCs were analyzed. We also analyzed the US findings of FTCs and FTAs.

Results: 16 nodules of 35 FTCs (45.7 %) and 19 nodules of 56 FTAs (33.9 %) harbored RAS mutations. Three FTCs and three FTAs showed two point mutations simultaneously. K-RAS codon 12-13 (n = 6, 31.6 %), N-RAS codon 61 (n = 5, 26.3 %), H-RAS codon 61 (n = 4, 21.1 %), K-RAS codon 61 (n = 3, 15.8 %), and N-RAS codon 12-13 (n = 1, 5.3 %) were found in FTCs, and N-RAS codon 61 (n = 10, 45 %), K-RAS codon 12-13 (n = 5, 22.7 %), H-RAS codon 61 (n = 5, 22.7 %), K-RAS codon 61 (n = 1, 4.5 %), and N-RAS codon 12-13 (n = 1, 4.5 %) were observed in FTAs. 4 of 56 (7.1 %) FTAs and 1 of 35 (2.9 %) FTCs represented PAX8/PPARγ rearrangements, respectively (P = 0.645). The absence of a hypoechoic rim (P = 0.021) and presence of calcifications (P = 0.049) were significantly associated with FTCs compared with FTAs.

Conclusions: RAS mutation frequency targeting the Korean population showed a 45.7 % in FTCs and 35.7 % in FTAs, and PAX8/PPARγ rearrangements were more frequently showed in FTAs. K-RAS codon 12-13 was the most common RAS mutation in FTCs, whereas N-RAS codon 61 was more frequent in FTAs. The presence of calcifications and absence of a hypoechoic rim showed more frequently in FTCs.

Citing Articles

Management of follicular thyroid carcinoma.

Yamazaki H, Sugino K, Katoh R, Matsuzu K, Kitagawa W, Nagahama M Eur Thyroid J. 2024; 13(5).

PMID: 39419099 PMC: 11558955. DOI: 10.1530/ETJ-24-0146.

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Shonka Jr D, Ho A, Chintakuntlawar A, Geiger J, Park J, Seetharamu N Head Neck. 2022; 44(6):1277-1300.

PMID: 35274388 PMC: 9332138. DOI: 10.1002/hed.27025.

Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.

Paulsson J, Rafati N, DiLorenzo S, Chen Y, Haglund F, Zedenius J J Clin Endocrinol Metab. 2021; 106(11):3265-3282.

PMID: 34171097 PMC: 8530729. DOI: 10.1210/clinem/dgab471.

Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review.

Odate T, Oishi N, Vuong H, Mochizuki K, Kondo T Gland Surg. 2020; 9(5):1813-1826.

PMID: 33224857 PMC: 7667107. DOI: 10.21037/gs-20-356.

Analysis of mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population.

Jeong S, Hong H, Lee E, Kwak J, Lee J Endocrinol Diabetes Metab. 2019; 1(4):e00040.

PMID: 30815568 PMC: 6354824. DOI: 10.1002/edm2.40.

References

DAvanzo A, Treseler P, Ituarte P, Wong M, Streja L, Greenspan F . Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004; 100(6):1123-9. DOI: 10.1002/cncr.20081. View

Banito A, Pinto A, Espadinha C, Marques A, Leite V . Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf). 2007; 67(5):706-11. DOI: 10.1111/j.1365-2265.2007.02949.x. View

Liu R, Hou C, You H, Huang C, Hock-Liew , Chou F . Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. Thyroid. 2004; 14(8):616-21. DOI: 10.1089/1050725041692882. View

Yoshimoto K, Iwahana H, Fukuda A, Sano T, Katsuragi K, Kinoshita M . ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res. 1992; 83(10):1057-62. PMC: 5918679. DOI: 10.1111/j.1349-7006.1992.tb02722.x. View

Marques A, Espadinha C, Catarino A, Moniz S, Pereira T, Sobrinho L . Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002; 87(8):3947-52. DOI: 10.1210/jcem.87.8.8756. View

Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry J, De Micco C . Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab. 2003; 88(6):2745-52. DOI: 10.1210/jc.2002-021186. View

Nikiforova M, Lynch R, Biddinger P, Alexander E, Dorn 2nd G, Tallini G . RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003; 88(5):2318-26. DOI: 10.1210/jc.2002-021907. View

Forbes S, Bindal N, Bamford S, Cole C, Kok C, Beare D . COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2010; 39(Database issue):D945-50. PMC: 3013785. DOI: 10.1093/nar/gkq929. View

Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P . Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999; 50(4):529-35. DOI: 10.1046/j.1365-2265.1999.00704.x. View

10.

Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y . The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid. 2012; 22(7):683-9. DOI: 10.1089/thy.2011.0261. View

11.

Park K, Koh J, Kim Y, Park H, Gong G, Hong S . Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf). 1998; 49(3):317-23. DOI: 10.1046/j.1365-2265.1998.00515.x. View

12.

Suarez H, Du Villard J, Severino M, Caillou B, Schlumberger M, TUBIANA M . Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990; 5(4):565-70. View

13.

Fernandez-Medarde A, Santos E . Ras in cancer and developmental diseases. Genes Cancer. 2011; 2(3):344-58. PMC: 3128640. DOI: 10.1177/1947601911411084. View

14.

Marques A, Espadinha C, Frias M, Roque L, Catarino A, Sobrinho L . Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer. 2004; 91(4):732-8. PMC: 2364771. DOI: 10.1038/sj.bjc.6601989. View

15.

Nikiforov Y . Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008; 21 Suppl 2:S37-43. PMC: 2673022. DOI: 10.1038/modpathol.2008.10. View

16.

Garcia-Rostan G, Zhao H, Camp R, Pollan M, Herrero A, Pardo J . ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003; 21(17):3226-35. DOI: 10.1200/JCO.2003.10.130. View

17.

Lin J, Chao T . Follicular thyroid carcinoma: From diagnosis to treatment. Endocr J. 2006; 53(4):441-8. DOI: 10.1507/endocrj.kr-77. View

18.

McIver B, Grebe S, Eberhardt N . The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 2004; 4(3):221-34. DOI: 10.2174/1568008043339802. View

19.

Grebe S, Hay I . Follicular thyroid cancer. Endocrinol Metab Clin North Am. 1995; 24(4):761-801. View

20.

DeLellis R . Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006; 94(8):662-9. DOI: 10.1002/jso.20700. View